Not a good buy right now: price is pushing into near-term resistance (~31.21) while options positioning (put-heavy open interest) and strong insider/hedge-fund selling point to capped upside in the immediate term.
Short-term technicals are only mildly bullish (MACD improving, RSI neutral), but there’s no high-conviction proprietary signal today to justify chasing.
Next major catalyst is earnings (2026-02-09 after hours). With recent quarterly profitability weakness and cautious Street target cuts, risk/reward favors waiting rather than buying immediately.
Trend/price action: Up +2.42% to 30.825, trading just above the pivot (30.505) and approaching first resistance (R1 31.21) — near-term upside may stall unless it cleanly breaks 31.21.
MACD: Histogram +0.0456 and expanding above zero -> improving bullish momentum.
RSI (6): 54.6 (neutral) -> not overbought, but not signaling a strong oversold entry either.
Moving averages: Converging -> consolidation/transition phase rather than a strong established trend.
Pattern-based stat provided: 50% chance of -0.7% next day, -1.17% next week, +5.2% next month -> near-term chop/softness, better odds on a 1-month horizon.
Options Data
Bearish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment: Open interest put/call 2.68 is notably put-heavy (bearish/hedging skew). Volume put/call 1.11 is mildly put-leaning (slightly bearish) rather than aggressive call speculation.
Activity: Today’s options volume is very low (19 contracts) versus 30-day averages (5D avg ~188.8; 10D avg ~229.4), so the day’s flow is not strongly informative.
Volatility: IV30 ~31.96 vs HV ~34.43 (IV slightly below realized). IV percentile 65.2 suggests options are not cheap; market is pricing a moderate level of uncertainty.
Positioning note: Put OI (16,770) materially exceeds call OI (6,265), reinforcing a defensive market posture around the name.
Technical Summary
Sell
3
Buy
11
Positive Catalysts
Earnings event ahead: QDEC 2025 earnings on 2026-02-09 (AH) with EPS estimate 1.11 could re-rate the stock if results/guide surprise positively.
Technical momentum improving: MACD expanding above zero and price holding above pivot supports a potential push to test 31.21/31.65 if buyers follow-through.
Street still has upside to targets: even recently reduced targets (e.g., 33–39 range) remain above the current ~30.8 price, implying potential medium-term upside if fundamentals cooperate.
Neutral/Negative Catalysts
suggests the market is positioned for downside protection rather than upside chase.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 5.416B, up +108.39% YoY (strong top-line growth).
Profitability: Net income 144M, down -112.16% YoY; EPS 0.27, down -113.37% YoY -> sharp deterioration in earnings power versus prior year (suggests one-offs, reserve/mark impacts, or margin pressure).
Takeaway: Growth looks strong on revenue, but the latest quarter shows material profit weakness, which aligns with the more cautious near-term sentiment and makes immediate buying less attractive ahead of earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Mostly price target reductions in early Jan 2026 (Barclays 39->35 Overweight; UBS 35->33 Neutral; BofA 40->39 Buy; JPM 40->39 Neutral). This is a cautious recalibration rather than a broad capitulation.
Rating mix: Still includes bullish views (BofA Buy, Barclays Overweight, Mizuho Outperform), but balanced by several Neutrals/Equal Weight and at least one prior downgrade (Morgan Stanley to Equal Weight).
Wall Street pros: Undervaluation potential in life insurers, generally healthy balance sheets, and possible macro tailwinds if conditions remain stable.
Wall Street cons: Sensitivity to rate cuts/spread compression, fewer near-term catalysts post transactions, and credit/earnings-quality risk — consistent with the pattern of target cuts.
Influential/political trading: No recent congress trading data available; no politician/influential figure transactions provided in the dataset.
Wall Street analysts forecast CRBG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBG is 37.3 USD with a low forecast of 33 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast CRBG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBG is 37.3 USD with a low forecast of 33 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 29.790
Low
33
Averages
37.3
High
40
Current: 29.790
Low
33
Averages
37.3
High
40
Barclays
Alex Scott
Overweight
downgrade
$39 -> $35
AI Analysis
2026-01-08
Reason
Barclays
Alex Scott
Price Target
$39 -> $35
AI Analysis
2026-01-08
downgrade
Overweight
Reason
Barclays analyst Alex Scott lowered the firm's price target on Corebridge to $35 from $39 and keeps an Overweight rating on the shares. The firm is "cautiously optimistic" on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. Barclays adjusted ratings and price targets as part of its 2026 outlook.
UBS
Neutral
downgrade
$35 -> $33
2026-01-08
Reason
UBS
Price Target
$35 -> $33
2026-01-08
downgrade
Neutral
Reason
UBS lowered the firm's price target on Corebridge to $33 from $35 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRBG
